[Antibodies against tumor associated antigens of human bronchogenic carcinoma: demonstration by anti-complement immunofluorescence (author's transl)]. 1981

H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp

A method of anti-complement immunofluorescence is described for semiquantitative measurement of antibodies in 281 sera samples obtained from patients with bronchogenic carcinoma. Tests were performed on frozen sections of 17 human bronchogenic carcinoma. - 168 sera obtained from healthy persons were used as control. Tumor and control sera were also tested on frozen sections of 10 normal lungs. - The intensity of fluorescence was measured by incident light with the aid of a Leitz microscope photometer. In comparison to control sera the mean values of fluorescence intensity of the tested 281 tumor sera were significantly higher when frozen sections of bronchogenic carcinoma were used. - In order to allow for the different content of antigens in the bronchogenic carcinoma we have calculated the rations of the tested tumor and control sera on tumor and normal sections. - The percentage of positive results showed strong dependence on the histological type of the bronchogenic carcinoma used as frozen section and differed between 16,3 and 69,1%. The highest percentage of positive reactions resulted when tumor sera were tested on frozen sections of undifferentiated bronchogenic carcinoma. Besides that sera from patients suffering from small cell bronchogenic carcinoma gave more positive results than sera from patients with other bronchogenic carcinoma. - In 78,3% of the carcinoma were tested on frozen sections of undifferentiated bronchogenic carcinoma.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000912 Antibodies, Neoplasm Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS. Neoplasm Antibodies,Tumor Antibodies,Antibodies, Tumor
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
March 1985, Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale B, Hygiene,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
April 1976, Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
July 1968, Surgery,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
January 1981, Archives of oto-rhino-laryngology,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
January 1975, Pathologia et microbiologia,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
December 1977, Journal of clinical microbiology,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
May 1986, Cancer research,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
July 1984, The Journal of urology,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
March 1970, Nature,
H W Schlipköter, and R Stiller-Winkler, and H Idel, and J Knopp
March 1988, Human cell,
Copied contents to your clipboard!